08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

MiR-103/107: Phase I started

AstraZeneca began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of subcutaneous AZD4076 in about 48 healthy male volunteers. The trial start triggered a $10 million milestone payment to Regulus from...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Regulus, AstraZeneca deal

Regulus disclosed in its 2013 earnings that it and partner AstraZeneca have selected microRNA-103 (miR-103) and miR-107 as targets under a 2012 deal to develop and commercialize preclinical miRNA therapeutics against three targets focused on...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-107 (miR-107) Patient and mice studies suggest inhibiting miR-107 could help treat breast cancer. Patients with longer survival had lower miR-107 levels than patients...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity MicroRNA-103 (miR-103); miR-107 A study in mice suggests antagonizing miR-103 and miR-107 could help treat obesity and type...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-107 (miR-107) In vitro, mouse and human studies suggest that increasing miR-107 levels could help treat cancer. In mice injected with human colon cancer...